CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of $0.07, $0.24 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $33.43 million versus the consensus estimate of $17.1 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.